Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10884864rdf:typepubmed:Citationlld:pubmed
pubmed-article:10884864lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:10884864lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:10884864lifeskim:mentionsumls-concept:C0008281lld:lifeskim
pubmed-article:10884864lifeskim:mentionsumls-concept:C0008269lld:lifeskim
pubmed-article:10884864lifeskim:mentionsumls-concept:C0024535lld:lifeskim
pubmed-article:10884864lifeskim:mentionsumls-concept:C0205178lld:lifeskim
pubmed-article:10884864lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:10884864lifeskim:mentionsumls-concept:C1705294lld:lifeskim
pubmed-article:10884864lifeskim:mentionsumls-concept:C0700599lld:lifeskim
pubmed-article:10884864pubmed:issue3lld:pubmed
pubmed-article:10884864pubmed:dateCreated2000-7-31lld:pubmed
pubmed-article:10884864pubmed:abstractTextOne hundred and eight children with acute, symptomatic, uncomplicated, falciparum malaria were randomized to receive chloroquine (for 3 days) plus chlorpheniramine alone (for seven days) (CQ-CP group; N = 55) or, in a sequential treatment, chloroquine plus chlorpheniramine for 3 days followed, on the fourth day, by a single oral dose of sulfadoxine-pyrimethamine (25 mg sulfadoxine/kg) (CQ-CP-SP group; N = 53). The mean (S.D.) parasite-clearance time in the CQ-CP group [2.1 (0.7) days; range = 1-5 days] was similar to that in the CQ-CP-SP [2.1 (0.8) days; range = 1-5 days]. The fever-clearance times were also similar: 1.2 (0.1) days (range = 1-3 days) v. 1.1 (0.4) days (range = 1-3 days). The cure rates on days 14, 21 and 28 were 98.2%, 96.3% and 92.7%, respectively in the CQ-CP group, and 100%, 100% and 96.2%, respectively, in the CQ-CP-SP group. The rates of gametocyte carriage were low and similar (5.4% in the CQ-CP group and 3.8% in the CQ-CP-SP group) throughout the duration of the study. Both treatment regimens were relatively well tolerated, the main adverse reactions being similar: sleepiness (on day 1) and pruritus (on days 1-3). No adverse effect was attributable to SP. The results indicate that sequential treatment, for 3 days with CQ and CP, followed by a single dose of SP, is effective and well tolerated in children with acute, uncomplicated, falciparum malaria and may be an alternative treatment for CQ- and/or SP-resistant falciparum malaria. Treatment with a CQ-CP combination (CQ and CP for 3 days and then CP alone for another 4 days) is also effective but requires continuing administration after the signs and symptoms of acute malaria have disappeared.lld:pubmed
pubmed-article:10884864pubmed:languageenglld:pubmed
pubmed-article:10884864pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10884864pubmed:citationSubsetIMlld:pubmed
pubmed-article:10884864pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10884864pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10884864pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10884864pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10884864pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10884864pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10884864pubmed:statusMEDLINElld:pubmed
pubmed-article:10884864pubmed:monthAprlld:pubmed
pubmed-article:10884864pubmed:issn0003-4983lld:pubmed
pubmed-article:10884864pubmed:authorpubmed-author:SowunmiAAlld:pubmed
pubmed-article:10884864pubmed:authorpubmed-author:AkinyinkaO...lld:pubmed
pubmed-article:10884864pubmed:authorpubmed-author:FaladeA GAGlld:pubmed
pubmed-article:10884864pubmed:authorpubmed-author:OduolaA MAMlld:pubmed
pubmed-article:10884864pubmed:authorpubmed-author:FaladeC OCOlld:pubmed
pubmed-article:10884864pubmed:authorpubmed-author:AdedejiA AAAlld:pubmed
pubmed-article:10884864pubmed:authorpubmed-author:FehintolaF...lld:pubmed
pubmed-article:10884864pubmed:issnTypePrintlld:pubmed
pubmed-article:10884864pubmed:volume94lld:pubmed
pubmed-article:10884864pubmed:ownerNLMlld:pubmed
pubmed-article:10884864pubmed:authorsCompleteYlld:pubmed
pubmed-article:10884864pubmed:pagination209-17lld:pubmed
pubmed-article:10884864pubmed:dateRevised2009-5-18lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:meshHeadingpubmed-meshheading:10884864...lld:pubmed
pubmed-article:10884864pubmed:year2000lld:pubmed
pubmed-article:10884864pubmed:articleTitleComparative efficacy of chloroquine plus chlorpheniramine alone and in a sequential combination with sulfadoxine-pyrimethamine, for the treatment of acute, uncomplicated, falciparum malaria in children.lld:pubmed
pubmed-article:10884864pubmed:affiliationDepartment of Pharmacology and Therapeutics, University of Ibadan, Nigeria. malaria.iba@alpha.linkserve.comlld:pubmed
pubmed-article:10884864pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10884864pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10884864pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:10884864pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:10884864pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10884864lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10884864lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10884864lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10884864lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10884864lld:pubmed